Cardior is a portfolio company of Fund+, a Belgian Venture Capital fund for long-term equity investment in innovative life sciences companies in Europe. Fund+ invested in Cardior’s Series B round in 2021, to bring the company’s main asset CDR132L into phase 2 clinical trials. Cardior perfectly exemplifies Fund+’s strategy of investing in therapeutics which address important unmet medical needs: heart failure currently affects more than 65 million people globally and though current therapies can slow disease progression, morbidity and mortality remain high.
Halina Novak, Principal at Fund+ and Board member of Cardior commented: “The acquisition of our portfolio company Cardior by Novo Nordisk for up to a billion euros is confirmation of the enormous potential this company’s RNA technology has in treating cardiovascular diseases. Social impact is important for Fund+, so we are thrilled to have contributed to the success of a promising European company en route to making a real difference in patient lives. It has been a privilege to work alongside the talented Cardior management team and the other investors – we will be watching future developments with great excitement.”
Cardior’s lead compound CDR132L is currently in phase 2 clinical development for the treatment of heart failure after myocardial infarction (commonly known as a heart attack). Novo Nordisk also plans to initiate a second phase 2 trial that will investigate CDR132L in a chronic heart failure population with cardiac hypertrophy – a condition that causes the walls of the heart muscle to become thick and stiff, affecting the heart’s ability to pump blood. “This acquisition is a reflection of CDR132L’s transformative potential as a disease-modifying therapy for heart failure,” said Claudia Ulbrich, MD, CEO and co-founder of Cardior.
Find out more in the full press release: https://cardior.de/news-events/
